Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions

Trial Profile

Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs OPA 15406 (Primary)
  • Indications Atopic dermatitis
  • Focus Pharmacokinetics
  • Sponsors Medimetriks Pharmaceuticals
  • Most Recent Events

    • 06 Sep 2017 Results published in a Medimetriks Pharmaceuticals Media Release.
    • 29 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 20 Jun 2017 Planned End Date changed from 1 Apr 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top